BioSpace News Archive

Harrow Health, Inc. today announced its acquisition of the exclusive U.S. commercialization rights of four FDA-approved ophthalmic medicines, IOPIDINE® 1% and 0.5% (apraclonidine hydrochloride), and MAXITROL® (neomycin and polymyxin B sulfate and dexamethasone) 3.5mg/10,000 units/0.1%, and MOXEZA® 0.5% (moxifloxacin hydrochloride), from Novartis.

Bruker today announced the release of the JPK NanoWizard® V BioAFM, a novel system that marks a milestone in automation and ease of use for life science atomic force microscopy research.

Palantir Technologies Inc. and Dewpoint Therapeutics today announced a partnership for Palantir’s Foundry platform to help power Dewpoint’s efforts to discover treatments and cures for the most challenging diseases.

Mednow Inc. is pleased to announce the Company will be hosting its quarterly conference call on Wednesday December 22, 2021 at 8:30am EST.

Eton Pharmaceuticals, Inc and ANI Pharmaceuticals, Inc (Nasdaq: ANIP), a bio-pharmaceutical company serving patients in need through the development and manufacturing of high-quality generic and branded medicines, today announced the commercial launch of Carglumic Acid tablets.

Cytokinetics, Incorporated (Nasdaq: CYTK) and Ji Xing Pharmaceuticals Limited today announced an expansion of their collaboration by entering into an exclusive license and collaboration agreement to develop and commercialize omecamtiv mecarbil for the proposed treatment of heart failure with reduced ejection fraction (HFrEF) in Greater China.

Aptose Biosciences Inc. (“Aptose”) (NASDAQ: APTO, TSX: APS) today announced its decision to discontinue further clinical development of APTO-253.

Organon (NYSE: OGN), announced today that Kevin Ali, Chief Executive Officer, and Matthew Walsh, Chief Financial Officer, are scheduled to participate in a fireside chat at the 40th Annual J.P. Morgan Healthcare Virtual Conference on Monday, January 10, 2022 at 2:15 p.m. ET.

Arrowhead Pharmaceuticals, Inc. announced that it has completed a transaction to purchase 13 acres of land in the Verona Technology Park in Verona, WI, which is planned to be the site of an approximately 140,000 square foot drug manufacturing facility and an approximately 115,000 square foot laboratory and office facility to support process development and analytical activities.

Achilles Therapeutics plc announced that the Company has been added to the NASDAQ Biotech Index, effective prior to market open, Monday, December 20, 2021.